Compare Stocks → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:EVLONASDAQ:GERNNASDAQ:MRKRNASDAQ:PRQRNASDAQ:XERS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVLOEvelo Biosciences$0.04$0.05$0.03▼$13.93$810K2.0322,406 shs1,279 shsGERNGeron$3.58+2.3%$2.80$1.64▼$4.05$1.91B0.629.96 million shs6.62 million shsMRKRMarker Therapeutics$4.40-0.5%$4.27$0.76▼$9.68$39.40M1.519,292 shs9,980 shsPRQRProQR Therapeutics$2.01-0.5%$2.14$1.11▼$3.29$164.34M0.21151,161 shs36,411 shsXERSXeris Biopharma$1.76-1.1%$2.35$1.46▼$3.26$250.01M2.331.44 million shs712,941 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVLOEvelo Biosciences+4.00%+0.57%-11.60%-35.85%-98.52%GERNGeron+2.29%-2.72%+9.82%+65.74%+47.93%MRKRMarker Therapeutics-0.68%+2.09%-8.52%+1.85%+385.76%PRQRProQR Therapeutics-0.50%+5.79%-15.90%-3.83%-9.46%XERSXeris Biopharma-1.12%-1.12%-16.59%-28.46%-20.36%Did You Get Your Free Bitcoin Yet? (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AGERNGeron3.2734 of 5 stars3.53.00.01.31.41.70.6MRKRMarker TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APRQRProQR Therapeutics1.4735 of 5 stars3.54.00.00.01.90.00.0XERSXeris Biopharma3.5743 of 5 stars3.52.00.04.20.02.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVLOEvelo Biosciences2.00HoldN/AN/AGERNGeron3.00Buy$5.3348.98% UpsideMRKRMarker TherapeuticsN/AN/AN/AN/APRQRProQR Therapeutics3.00Buy$3.6079.10% UpsideXERSXeris Biopharma3.00Buy$4.88176.99% UpsideCurrent Analyst RatingsLatest PRQR, MRKR, XERS, EVLO, and GERN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024PRQRProQR TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.80 ➝ $2.004/11/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/10/2024GERNGeronWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$6.003/28/2024XERSXeris BiopharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.003/15/2024GERNGeronWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$6.003/15/2024GERNGeronThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.003/15/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.003/14/2024PRQRProQR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$2.00 ➝ $2.503/14/2024PRQRProQR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/7/2024XERSXeris BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.50 ➝ $6.002/28/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVLOEvelo BiosciencesN/AN/AN/AN/A($0.92) per shareN/AGERNGeron$240K8,157.48N/AN/A$0.46 per share7.78MRKRMarker Therapeutics$3.31M11.83N/AN/A$1.58 per share2.78PRQRProQR Therapeutics$7.05M23.20N/AN/A$0.55 per share3.65XERSXeris Biopharma$163.91M1.51N/AN/A($0.05) per share-35.20Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVLOEvelo Biosciences-$114.53M-$13.29N/A∞N/AN/AN/A-189.58%5/13/2024 (Estimated)GERNGeron-$184.13M-$0.33N/AN/AN/A-77,691.14%-63.33%-44.71%5/9/2024 (Estimated)MRKRMarker Therapeutics-$8.24MN/A0.00∞N/A-142.62%-39.89%-25.45%5/21/2024 (Estimated)PRQRProQR Therapeutics-$30.43M-$0.39N/AN/AN/A-431.65%-56.71%-19.15%5/21/2024 (Estimated)XERSXeris Biopharma-$62.26M-$0.45N/AN/AN/A-37.98%-610.76%-19.15%5/14/2024 (Estimated)Latest PRQR, MRKR, XERS, EVLO, and GERN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/13/2024Q4 2023PRQRProQR Therapeutics-$0.08-$0.08N/A-$0.08$27.88 million$3.54 million3/6/2024Q4 2023XERSXeris Biopharma-$0.09-$0.10-$0.01-$0.10$45.50 million$44.39 million 2/28/2024Q4 23GERNGeron-$0.10-$0.09+$0.01-$0.09$0.06 million$0.02 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVLOEvelo BiosciencesN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVLOEvelo BiosciencesN/A0.480.48GERNGeron0.143.163.16MRKRMarker TherapeuticsN/A5.575.57PRQRProQR Therapeutics0.103.543.54XERSXeris Biopharma49.271.641.23OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVLOEvelo Biosciences0.31%GERNGeron73.71%MRKRMarker Therapeutics22.39%PRQRProQR Therapeutics32.65%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipEVLOEvelo Biosciences1.02%GERNGeron3.10%MRKRMarker Therapeutics24.10%PRQRProQR Therapeutics8.40%XERSXeris Biopharma4.36%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEVLOEvelo Biosciences6618.98 million18.79 millionNo DataGERNGeron141546.87 million529.92 millionOptionableMRKRMarker Therapeutics88.90 million6.76 millionNot OptionablePRQRProQR Therapeutics15681.36 million74.52 millionOptionableXERSXeris Biopharma377140.45 million134.33 millionOptionablePRQR, MRKR, XERS, EVLO, and GERN HeadlinesSourceHeadlineXeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutionsfinance.yahoo.com - April 5 at 12:23 PMXeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)finance.yahoo.com - April 3 at 6:23 PMXeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conferencefinance.yahoo.com - April 2 at 8:50 AMXeris Biopharma (NASDAQ:XERS) Now Covered by Oppenheimermarketbeat.com - March 28 at 8:29 AMXeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for 2024 Growthproactiveinvestors.com - March 18 at 9:49 PMHere's What Analysts Are Forecasting For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) After Its Annual Resultsfinance.yahoo.com - March 9 at 1:59 PMXeris Biopharma (XERS) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 8 at 7:43 PMXeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023finance.yahoo.com - March 7 at 2:41 PMXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcriptinsidermonkey.com - March 7 at 1:01 PMQ4 2023 Xeris Biopharma Holdings Inc Earnings Callfinance.yahoo.com - March 7 at 12:19 AMXeris Biopharma Shares Drop After Weak 4Q Resultsmarketwatch.com - March 6 at 7:18 PMXeris Pharmaceuticals GAAP EPS of -$0.10 in-line, revenue of $44.39M beats by $0.84Mmsn.com - March 6 at 7:18 PMXERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023investorplace.com - March 6 at 2:00 PMXeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jumpproactiveinvestors.com - March 6 at 9:57 AMXeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimateszacks.com - March 6 at 9:16 AMXeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Eventsbusinesswire.com - March 6 at 7:02 AMXeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capitalbusinesswire.com - March 6 at 7:00 AMWhy Xeris (XERS) Might Surprise This Earnings Seasonzacks.com - March 5 at 10:46 AMXeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024businesswire.com - February 28 at 7:00 AM3 Breakout Stocks Under $5 to Buy for More Upsidetheglobeandmail.com - February 23 at 7:13 PMXeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conferencefinance.yahoo.com - February 5 at 9:27 AMBig Game or Small, Here's How to Go About Stalking a Traderealmoney.thestreet.com - February 3 at 6:45 PMXeris inks licensing deal with Amgen on former Horizon drugchicagobusiness.com - January 12 at 9:32 AMXeris Biopharma jumps on news of Amgen dealthepharmaletter.com - January 12 at 9:32 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEvelo BiosciencesNASDAQ:EVLOEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.GeronNASDAQ:GERNGeron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Marker TherapeuticsNASDAQ:MRKRMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company also develops MT-401-OTS, which is in phase 1 clinical trial for the treatment of acute myeloid leukemia; and MT-601 which is in phase 1 clinical trial for the treatment of lymphoma, as well as in phase 1/2 clinical trial for the treatment of pancreatic cancer. Marker Therapeutics is headquartered in Houston, Texas.ProQR TherapeuticsNASDAQ:PRQRProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.Xeris BiopharmaNASDAQ:XERSXeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.